Skip to main content
. 2023 Mar 30;41(16):2963–2974. doi: 10.1200/JCO.22.02120

FIG 2.

FIG 2.

(A) EFS, (B) CIR, and (C) OS curves of patients with EOI2 MRD negativity and MRD positivity. (D) EFS, (E) CIR, and (F) OS curves of patients with EOI2 MRD negativity and MRD positivity stratified by KMT2A fusion partner-based risk group. The group of patients with EOI2 MRD negativity included patients who were EOI1 MRD-negative and EOI2 MRD-negative (– –), as well as patients who were EOI1 MRD-positive and EOI2 MRD-negative (+ –). The group of patients with EOI2 MRD positivity included patients who were EOI1 MRD-positive and EOI2 MRD-positive (+ +), as well as patients who were EOI1 MRD-negative and EOI2 MRD-positive (– +). CIR, cumulative incidence of relapse; EFS, event-free survival; EOI1, end of induction 1; EOI2, end of induction 2; MRD, measurable residual disease; OS, overall survival.